Fidelity® Select Biotechnology Portfolio
(FBIOX)
US Markets Open
AdChoices
217.68
+4.25
+1.99%
:

Previous Close

213.43

Net Assets

9.17B

Yield

0.00%

Front load

None

Expenses

0.75%

Category

Health

Morningstar Risk

High

Morningstar Rating ★★★★
AdChoices
Performance
Returns %
Key statistics
  • Composition
  • Performance
  • Top Holdings
  • Top Rated Funds
  • Fund vs. Category
Quarterly Returns
  • Annual

  • FBIOX

  • Category

    • 2013

    • 65.66%

    • -

    • 2012

    • 36.59%

    • -

    • 2011

    • 18.18%

    • -

    • 2010

    • 11.41%

    • -

    • 2013

    • 2012

    • 2011

      • Q1

      • 20.37%

      • 19.93%

      • 7.55%

      • Q2

      • 7.11%

      • 6.99%

      • 10.17%

      • Q3

      • 23.79%

      • 9.85%

      • -12.74%

      • Q4

      • 3.80%

      • -3.09%

      • 14.30%

      Composition
      Sector Weightings
      Equity Investment Style
      The two dimensions of the Fund Style box measure the average size of companies that have been in the FUND, from the top to bottom, and the average valuation characteristics of the FUND's past stock holdings, from left to right.
      • Name

      • % Portfolio Weight

      • Shares Held

      • Change

        • Gilead Sciences Inc

        • 13.20

        • 11,357,006

        • -1,440,679

        • Vertex Pharmaceuticals Inc

        • 5.39

        • 5,331,394

        • 0

        • Celgene Corp

        • 4.68

        • 4,561,251

        • 1,093,520

        • Regeneron Pharmaceuticals Inc

        • 3.97

        • 1,047,685

        • 279,964

        • Alexion Pharmaceuticals Inc

        • 3.80

        • 2,079,172

        • 638,386

        • Intercept Pharmaceuticals Inc

        • 3.64

        • 1,162,568

        • 0

        • Puma Biotechnology Inc

        • 3.39

        • 1,204,627

        • 34,626

        • Medivation Inc

        • 2.40

        • 2,433,685

        • 0

        • Biogen Idec Inc

        • 1.82

        • 490,207

        • -219,409

        • Biomarin Pharmaceutical Inc

        • 1.79

        • 2,328,644

        • 0

        • Name

        • Rating

        • YTD Return %

          • Prudential Jennison Health Sciences A LW

          • ★★★★★
          • 18.54

          • VALIC Company I Health Sciences

          • ★★★★★
          • 19.62

          • Prudential Jennison Health Sciences Z

          • ★★★★★
          • 18.82

          • T. Rowe Price Health Sciences

          • ★★★★★
          • 19.88

          • JHFunds2 Health Sciences NAV

          • ★★★★
          • 19.74

          • Janus Global Life Sciences A

          • ★★★★
          • 20.34

          • Janus Global Life Sciences C

          • ★★★★
          • 19.57

          • Janus Global Life Sciences I

          • ★★★★
          • 20.60

          • Janus Global Life Sciences S

          • ★★★★
          • 20.19

          • Janus Global Life Sciences A LW

          • ★★★★
          • 20.34

          • Name

          • FBIOX

          • Category

            • Expense Ratio

            • 0.75%

            • 1.45%

            • Net Assets

            • 9.17B

            • 711.24M

            • Dividend Yield

            • 0.01%

            • 0.61

            • Price/Book

            • 7.20

            • 4.82

            • Price/Sales

            • 11.52

            • 3.25

            • Price/Cash Flow

            • 11.42

            • 19.29

            Profile

            Name of Issuer

            Fidelity Investments

            Fund Style

            Open

            Fund Manager

            Rajiv Kaul

            Investment Style

            Medium Growth

            The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.

            Purchase Information

            Initial Purchase 2,500
            Initial Purchase: IRA 500
            Initial Purchase: AIP 2,500
            Front load None
            Back Load None

            Inception

            12/16/1985